Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Isatuximab in Relapsed/Refractory T-ALL or T-LBL
NCT02999633Phase 2Terminated
- Sponsor
- Sanofi
- Start
- Mar 2017
- Primary completion
- Nov 2017
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 7
01
Overview
Phase 2, open-label, single-arm trial of isatuximab in t-cell acute lymphoblastic leukemia (T-ALL) and T cell lymphoblastic lymphoma (T-LBL), sponsored by Sanofi. Primary endpoint: Objective Response Rate at 12.1 weeks. Started Mar 2017; status: terminated.
02
Drugs
isatuximab
03
Conditions
t-cell acute lymphoblastic leukemia (T-ALL)T cell lymphoblastic lymphoma (T-LBL)
Beyond the preview
Go deeper on NCT02999633.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02999633.